Padmanabh P. Bhatt
CIK: 0001539215
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SUPERNUS PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (63 total)
- Oct 30, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
100K shares- - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct2.5K shares- - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct1.2K shares at avg. $46.57$54K - Jul 29, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
2.5K shares- - Mar 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct412 shares at avg. $50.48$21K - Mar 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct6.8K shares at avg. $49.55$339K - Mar 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct7.3K shares at avg. $39.40$286K - Mar 17, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct27.7K shares at avg. $49.95$1.4M - Mar 17, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct22.3K shares at avg. $50.73$1.1M - Mar 17, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct15K shares at avg. $38.60$579K - Mar 17, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct12.3K shares at avg. $36.75$450K - Mar 17, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct22.8K shares at avg. $39.40$896K - Mar 16, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct4.3K shares at avg. $29.61$126K - Mar 16, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct22.8K shares at avg. $36.75$836K - Mar 16, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct34.1K shares at avg. $50.18$1.7M - Mar 16, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct5K shares at avg. $27.94$140K - Mar 16, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct18K shares at avg. $32.20$580K - Mar 16, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct15.9K shares at avg. $50.49$802K - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct650 shares at avg. $50.69$33K - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.3K shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.3K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct581 shares at avg. $51.35$30K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.1K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct646 shares at avg. $50.86$33K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 30, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 100,000 | - | - | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 2,500 | - | $0 | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 1,158 | $46.57 | $53,928 | Direct |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 2,500 | - | - | Direct |
| Mar 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 412 | $50.48 | $20,798 | Direct |
| Mar 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 6,838 | $49.55 | $338,823 | Direct |
| Mar 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 7,250 | $39.40 | $285,650 | Direct |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 27,710 | $49.95 | $1,384,115 | Direct |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 22,290 | $50.73 | $1,130,772 | Direct |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 15,000 | $38.60 | $579,000 | Direct |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 12,250 | $36.75 | $450,188 | Direct |
| Mar 17, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 22,750 | $39.40 | $896,350 | Direct |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 4,250 | $29.61 | $125,843 | Direct |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 22,750 | $36.75 | $836,063 | Direct |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 34,114 | $50.18 | $1,711,841 | Direct |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 5,000 | $27.94 | $139,700 | Direct |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 18,000 | $32.20 | $579,600 | Direct |
| Mar 16, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 15,886 | $50.49 | $802,084 | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 650 | $50.69 | $32,949 | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,250 | - | $0 | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,250 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 581 | $51.35 | $29,834 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,125 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 646 | $50.86 | $32,856 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,250 | - | $0 | Direct |
1-25 of 63 transactions
About Bhatt Padmanabh P.
Bhatt Padmanabh P. (SEC CIK 0001539215) files insider reports with the SEC as Sr. VP of IP, CSO of SUPERNUS PHARMACEUTICALS, INC. (SUPN).
Signal8 holds 18 ownership filings by Bhatt Padmanabh P., all Form 4s, filed between Dec 4, 2024 and Nov 2, 2026. Those filings report 63 transactions, from Dec 3, 2024 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bhatt Padmanabh P.'s filings is in ROCKVILLE, MD.
Recent filings by Bhatt Padmanabh P.
- Oct 30, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Aug 12, 2026: Option exercise of SUPN shares (Form 4, code M).
- Aug 12, 2026: Tax withholding of SUPN shares (Form 4, code F).
- Jul 29, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Mar 18, 2026: Open-market sales of SUPN shares (2 lines, Form 4, code S).
Other insiders filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Khattar Jack A., President, CEO
- Rubin Jonathan, SVP, Chief Medical Officer
- DEC TIMOTHY C, Senior Vice-President & CFO
- Mottola Frank, SVP, Chief Tech. Ops. Officer
- Horich William Todd, SVP, Commercial Operations
- Hudson Frederick M., Director